INBX stock fell 1.22 percent after Q2 earnings missed estimates

Published on 10/07/2026 at 07:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inhibrx Biosciences stock carried a USD 1.4 billion market value on October 6, 2026, with 169,420 shares traded. Its 52-week span was USD 28.16 to USD 155.29.

INBX, US45720N1037, Illustration mit AI erstellt.

Inhibrx Biosciences (ISIN US45720N1037) closed at USD 93.41 on Nasdaq on October 6, 2026, down 1.22 percent from the prior session. The company’s Q2 2026 diluted EPS came in at negative USD 2.34, missing the consensus estimate by USD 0.06, according to MarketBeat on August 13, 2026.

Q2 loss misses expectations

The Q2 result gives the stock a measurable earnings checkpoint: diluted EPS was negative USD 2.34 against a negative USD 2.28 consensus estimate. The USD 0.06 shortfall followed a larger negative EPS result of USD 2.15 in Q1 2026, based on the standardized quarterly figures for the periods ended March 31 and June 30, 2026.

Inhibrx is a clinical-stage biotechnology company developing engineered biologic therapies for serious diseases. Its investor materials describe a modular protein-engineering platform and identify INBRX-109 and INBRX-106 among its clinical candidates, as stated by Inhibrx Biosciences on its investor page.

Analyst targets remain widely spaced

According to MarketBeat on October 3, 2026, six brokerages gave Inhibrx a Moderate Buy consensus, with an average 12-month price target of USD 197.50. The published ratings consisted of one sell, two holds, two buys and one strong buy, showing a broad range of views around a clinical-stage pipeline.

A separate MarketBeat overview placed the high target at USD 245.00 and the low target at USD 150.00. Against the October 6 closing price, the average target lies 111.4 percent above the price, a spread that reflects both development potential and clinical execution risk.

Stock trades below yearly high

INBX had a market capitalization of USD 1.4 billion and volume of 169,420 shares on October 6, 2026. Its 52-week range was USD 28.16 to USD 155.29, leaving the close USD 61.88 below the yearly high and USD 65.25 above the yearly low.

The market is therefore weighing a negative quarterly earnings comparison against a biotechnology pipeline that analysts value well above the current share price. For investors, the next material test is whether clinical progress can improve the earnings profile before cash consumption and further development spending dominate the valuation debate.

INBX closes at USD 93.41

Inhibrx Biosciences closed at USD 93.41 on Nasdaq on October 6, 2026, with a daily change of negative 1.22 percent. The closing price, market value and 52-week range place the stock below its yearly peak while the analyst average remains substantially higher.